Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy
Collectively, the current data support the GHS/QoL benefit of first-line cemiplimab monotherapy versus chemotherapy overall and in multiple subpopulations of patients with programmed cell death-ligand 1 expression ≥50% advanced non-small cell lung cancer.
Authors
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- Frank Seebach
- Eric Yan (ORCID: https://orcid.org/0000-0001-7390-0403)
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Xue Jia (ORCID: https://orcid.org/0009-0006-5937-8931)
- Saadettin Kilickap
- David R. Gandara
- Mahmut Gümüş
- Eric Kim
- Ahmet Sezer
- Ruben G. W. Quek
- Mustafa Özgüroğlu
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- PAREXEL International (United States) (US)
- University of California Davis Medical Center (US)
- Istanbul Medeniyet University (TR)
- Tbilisi State Medical University (GE)
- Dnipro State Medical University (UA)
- Cytel (United States) (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1002/cncr.70339
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals